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lObjectives: To assess the cost-effectiveness of blood pressure (BP)-
lowering and cholesterol-lowering drugs for cardiovascular disease
(CVD) prevention.Methods: We constructed a Markovmodel in which
the Thai population was classified by 10-year absolute CVD risk and
modeled the use of BP- and cholesterol-lowering drugs, including a
“polypill” (three BP-lowering drugs and a statin). We applied “do-noth-
ing” as the comparator, a health sector perspective on lifetime cost-
effectiveness, 3% discounting of costs and effects, and used probabilis-
tic sensitivity analysis. Outcomes are expressed as average and
incremental cost-effectiveness in Thai baht per disability-adjusted life-
year averted. Results: The polypill would be a very cost-effective op-5%–9.9%). Use of the three most cost-effective BP drugs is also associ- O
e no
atta
al So
doi:10.1016/j.vhri.2012.03.019ted with a net cost saving and large health gain at risk levels greater
han 5%. Adding a generic statin gives a price per disability-adjusted
ife-year of 0.5 (10-year risk at 20%) to 1.5 (10-year risk at 5%–9.9%)
imes Thai per-capita gross domestic product using lowest available
nnual costs. However, at current average drug prices, adding a statin
ould be considered cost-effective only for those with a 10-year abso-
ute CVD risk of 20% and more. Conclusions: Primary CVD prevention
ith the polypill or a combination of three generic BP-lowering drugs is
ery cost-effective in the Thai population.
eywords: blood pressure–lowering drugs, cardiovascular disease, cho-
esterol-lowering drugs, cost-effectiveness, Thailand.tion for CVD prevention even in people at modest risk (10-year risk of Copyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Cardiovascular diseases (CVDs) are among the leading causes of
health loss worldwide [1] and in Thailand [2,3]. CVD results in
high case-fatality rates during the first few days following an
event [4,5], an ongoing increased risk of death [6,7] among those
who survive the initial event, and a high cost of treatment [8].
Exposure to important CVD risk factors such as raised blood
pressure (BP) and cholesterol, tobacco use, and diabetes melli-
tus is rising in Thailand [9]. These factors are related to changes
in lifestyle, including an increase in sedentary behavior and a
change in diet. As observed in manyWestern countries, preven-
tive action can reduce the incidence and premature mortality
due to CVD [10,11].
BP- and cholesterol-lowering drugs have been proven to be
effective in preventing ischemic heart disease (IHD) and stroke
[12,13]. Given limited health care resources, Thailand’s health
policy needs to be based not only on effectiveness but also on
associated costs to determine which intervention(s) should be
Conflicts of interest: The authors have indicated that they hav
* Address correspondence to: Panrasri Khonputsa, 59/313 Piboonw
Thailand.
E-mail: panarasik@yahoo.com.
2212-1099/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.publicly funded and what population should be targeted. Iden-
tifying population subgroup(s) that should be targeted with in-
terventions can be based on estimates of future risks of CVD.
Recent guidelines have advocated the use of individuals’ “abso-
lute CVD risks” as the criterion for the initiation of preventive
drug therapies. For each individual, this absolute CVD risk is
calculated on the basis of exposure to various determinants of
CVD incidence and mathematical formulae such as the
Framingham Risk Score, the Systematic Coronary Risk Evalua-
tion, and cardiovascular risk prediction tools for populations in
Asia [14–16].
Cost-effectiveness of BP- and cholesterol-lowering medica-
tions has been studied elsewhere; however, results differ from
setting to setting [17–19]. Furthermore, studies on cost-effective-
ness show differences in methodology, outcomes, cost compo-
nents, and characteristics of the target population [17]. To our
knowledge, there have been no studies reporting the cost-effec-
tiveness of BP- and cholesterol-lowering drugs, singly or in com-
bination, for CVD prevention in Thailand.
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We assessed the cost and effectiveness of different BP- and cho-
lesterol-lowering drugs targeting population subgroupswith vary-
ing absolute CVD risk levels.
Methods
This study was carried out as part of Setting Priorities using Infor-
mation on Cost Effectiveness project, a collaborative project be-
tween theMinistry of Public Health of Thailand and the University
of Queensland, School of Population Health, Australia.
Definitions, incidence, and case-fatality rates of CVD
We defined a new case of CVD as a first-ever fatal or nonfatal IHD
or stroke event, including unstable angina pectoris, myocardial
infarction, ischemic stroke, or hemorrhagic stroke.
There was no direct information on the incidence and case-
fatality rates of CVD in Thailand; we estimated these by using
hospital admissions data and mortality data. These two locally
available data sources provided estimates of the incidence of fatal
and nonfatal IHD/stroke. Hospital admission data were provided
by the Ministry of Public Health, which uses these data to reim-
burse public hospitals. Because the database does not capture pri-
vate hospital admissions, we inflated all admissions to reflect the
total number of self-reported hospital admissions by age, sex, and
hospital level from the 2005 Health and Welfare Survey (National
Statistics Office, Bangkok, Thailand). The vital registration system
has unacceptably high proportions of deaths coded to ill-defined
Table 1 – Effectiveness parameters used in cost-effectivene
drugs.
Parameter Point estim
D
First-year discontinuation rate 50% (37.5%–62.5%)
for polypill
Uniform distribu
Relative risk Ischemic heart
disease
Ischemic
Diuretic 0.86 (0.75–0.98
Lognormal distribution
0.62 (0.53–0.7
Lognormal d
ACEI 0.83 (0.78–0.89)
Lognormal distribution
0.78 (0.66–0.9
Lognormal d
BB 0.89 (0.78–1.02)
Lognormal distribution
0.83 (0.70–0.9
Lognormal d
CCB 0.78 (0.62–0.99)
Lognormal distribution
0.66 (0.58–0.7
Lognormal d
Statin 0.77 (0.74–0.80
Lognormal distribution
0.78 (0.70–0.8
Lognormal d
ARB 0.86 (0.53–1.40)
Lognormal distribution
0.79 (0.69–0.9
Lognormal d
Polypill* 0.44 (0.34–0.54)
Lognormal distribution
0.32 (0.24–0.4
Lognormal d
Current practice
(men, women)
0.99, 0.98 0.99,
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-rec
* Polypill cost is based on the sum of the costs for each drug compone
in drug preparation.causes, and so we used data from a recent cause-of-death study.The study was well designed and conducted by using standard
methods [3,20–22].
Current practice
To assess the cost-effectiveness of current practice, we first esti-
mated its average yearly cost by adding the weighted yearly cost of
the three drug components currently used: BP-lowering drugs, cho-
lesterol-lowering drugs, and the combination. Similarly, the overall
effects of current practice on IHD, ischemic stroke, and hemorrhagic
stroke were calculated, separately, as the sum of the effects of BP-
lowering drugs as one group, cholesterol-lowering drugs as another
group, and the combination of these as a third group.
Interventions analyzed
We selected BP- and cholesterol-lowering drug interventions that
have been proven in clinical trials to be effective in preventing IHD
and stroke [12,13]. BP-lowering drugs were classified into five sub-
classes: thiazide diuretics (Ds), calcium channel blockers (CCBs),
beta blockers, angiotensin-converting enzyme inhibitors (ACEIs),
and angiotensin receptor blockers (ARBs). Statins were selected as
the most cost-effective cholesterol-lowering drugs available as a
generic in Thailand. The analysis was conducted for single drug
interventions and combinations of drugs from different classes.
When two or more drugs were used together, their effects, mea-
sured as the relative risk (RR) of disease incidence, were combined
by using a multiplicative equation (e.g., RR1 RR2 RR3) [23]. We
also analyzed the cost-effectiveness of a theoretical “polypill” [11]
composed of a statin [12] in full dose and three BP-lowering drugs
in half standard doses (D, CCB, and ACEI) [13]. This combination
was selected on the basis of superior effects of the three drugs and
nalysis of blood pressure– and cholesterol-lowering
ncertainty range)
ibution
Source
gle drugs, 40% (30%–50%) Estimate
ke Hemorrhagic stroke
ution
0.62 (0.53–0.72)
Lognormal distribution
Law et al. [13]
ution
0.78 (0.66–0.92)
Lognormal distribution
Law et al. [13]
ution
0.83 (0.70–0.99)
Lognormal distribution
Law et al. [13]
ution)
0.66 (0.58–0.75)
Lognormal distribution
Law et al. [13]
ution
1.00 Cholesterol Treatment
Trialists’ (CTT)
Collaborator [12]
ution
0.79 (0.69–0.90)
Lognormal distribution
Law et al. [13]
ution
0.41 (0.31–0.52)
Lognormal distribution
Estimate based on the
multiplicative
effects of drug
components
0.98, 0.97 Estimate based on
proportion using
drugs currently
r blocker; BB, beta blocker; CCB, calcium channel blocker.
owever, the true cost is likely to be less because of economies of scaless a
ate (u
istr
for sin
tion
stro
2)
istrib
2)
istrib
9)
istrib
5)
istrib
7)
istrib
0)
istrib
1)
istrib
0.97
epto
nt. Htheir cost-effectiveness over beta blockers and ARBs (Table 1).
a17V A L U E I N H E A L T H R E G I O N A L I S S U E S 1 ( 2 0 1 2 ) 1 5 – 2 2We did not include aspirin in the polypill because the addition
of aspirin contributesminimal additional effectiveness. Moreover,
aspirin can cause serious side effects of gastrointestinal and intra-
cranial bleeds, particularly in the elderly [24,25].
Target populations
The target populationwas classified on the basis of the probability
of developing a cardiovascular event over the next 10 years. Risks
were estimated by using risk prediction equations we developed
for Thailand on the basis of the calibration of the Framingham
equations [26] taking into account the contemporary incidence of
IHD and stroke. Risk factors included age, systolic BP, total choles-
terol, diabetes mellitus, and smoking, with separate equations for
males and females and for IHD and stroke. The population was
divided into four risk categories: 5%, 5% to 9.9%, 10% to 19.9%,
nd 20% risk of IHD or stroke over the next 10 years.
Perspective and cost
The costs associated with the implementation of each interven-
tion were estimated from a health sector perspective; that is, we
included the costs to government as well as the health interven-
tion–related costs to patients and their family/carers. Intervention
costs included pharmaceuticals, health center visits for 20 min-
utes (one visit to a specialist [obtained from the National Statistics
Office, Bangkok, Thailand] and two to a primary care center [27]
per year), and laboratory tests (an annual test of urea and electro-
lytes for BP-lowering drugs, and of lipids and liver enzymes for
cholesterol-lowering drugs). We obtained the cost of drugs from
Table 2 – Cost parameters used in cost-effectiveness analy
Parameter Point estim
D
Quantities
Number of long health center visits (each year)
Number of short health center visits (each year)
Number of tests for lipid levels (each year)
Number of tests for liver function (each year)
Number of tests for serum urea and electrolyte
levels (each year)
Price per unit
1  long health center visit
Uniform
1  short GP visit
Uniform
1  test for urea and electrolyte levels
Uniform
1  test for lipid levels and liver function
Uniform
Annual cost of diuretic
Uniform
Annual cost of ACEI
Uniform
Annual cost of BB
Uniform
Annual cost of CCB
Uniform
Annual cost of statin 5
Uniform
Annual cost of ARB 8
Uniform
Annual cost of polypill 7
Uniform
Annual cost of current practice 294 for
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin-rec
practitioner.theWeb page of the Ministry of Public Health [28]. Drug costs usedin base-case analysis were the lowest annual costs (for generic
versions of the drugs), whereas ranges used in the probabilistic
sensitivity analysis were between the lowest and the highest
costs. When two or more BP-lowering drugs were combined, the
cost of health center visits and laboratory tests were the same as
for a single drug. For the combinations of BP- and cholesterol-
lowering drugs, the cost of a health center visit was counted only
once and the costs of laboratory tests were added. The cost of
polypill interventionwas the sumof the costs of eachdrug and one
visit to a health center with no cost of laboratory tests.
We also included cost-offsets, that is, the cost of disease treat-
ments that are avoided by prevention. The cost of IHD treatment
was readily available [8]. Costs of stroke treatment were obtained
from the Neurological Institute in Bangkok. All costs were con-
verted into the 2004 baht value by using the consumer price index
[29]. Drug costs and other costs associated with the implementa-
tion of interventions (costs of health center visits and laboratory
tests) are shown in Table 2.
Model and transition probabilities
We developed a Markov model to assess the net costs and health
outcomes associated with lifetime use of BP- and/or cholesterol-
lowering drugs in the primary prevention of CVD. The model was
implemented in Microsoft Excel (Microsoft Corp., Redmond, WS).
Each age, sex, and absolute risk category was modeled separately
to death or 100 years of age, but we present aggregate results for
the whole eligible target population in 2004 only. Costs and out-
comes were discounted at 3%. Four health states were explicitly
f blood pressure– and cholesterol-lowering drugs.
ncertainty range)
ibution
Source
1 Estimate
2 Estimate
1 Estimate
1 Estimate
1 Estimate
20–200)
ribution
The National Statistical Office of Thailand
8–163)
ribution
World Health Organization
96–326)
ribution
The Faculty of Medical Technology,
Chiang Mai University
42–570)
ribution
The Faculty of Medical Technology,
Chiang Mai University
8–99)
ribution
The Ministry of Public Health
04–370)
ribution
The Ministry of Public Health
32–588)
ribution
The Ministry of Public Health
95–361)
ribution
The Ministry of Public Health
3–2132)
ribution
The Ministry of Public Health
2–1444)
ribution
The Ministry of Public Health
0–2565)
ribution
The Ministry of Public Health
414 for women The Ministry of Public Health
blocker; BB, beta blocker; CCB, calcium channel blocker; GP, generalsis o
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istr
160 (1
dist
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dist
456 (3
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tween these mutually exclusive health states could occur at the
end of discrete yearly cycles (Fig. 1).
Model assumptions
The effects of these three BP-lowering drugs in the polypill [13] in
alf standard doses were assumed to be 20% lower than those in
tandard doses [23]. The effects of the polypill were assumed to be
multiplication of the effects of the four drugs. We assumed that
he greater convenience of taking just one pill would enhance ad-
erence and that there would be fewer side effects and less need
or repeated measurement of risk factor levels [23,30]. We as-
umed 60% adherence for the polypill. Adherence to single drugs
n full doses was assumed to be 50% [19]. The effect sizes for each
rug are shown in Table 1. The cost associated with discontinua-
ion was assumed to be the sum of one health center visit, one
aboratory test, and 1month of drug costs. No health benefitswere
ssumed for persons who discontinued their medication.
Do nothing as a comparator
The cost-effectiveness of interventions was compared with a “do
nothing” scenario [31], which was quantified by removing the
costs and effects of the BP- and cholesterol-lowering medications
used in current practice.
Cost-effectiveness ratios
Starting from this hypothetical “do nothing” situation, we first
calculated the average cost-effectiveness ratio (ACER) for each in-
tervention. The ACER is equal to the difference in cost between the
intervention and the “do nothing” scenario divided by the differ-
ence in health outcomes between the two scenarios in disability-
adjusted life-years averted. The cost was calculated as the inter-
vention cost minus the averted costs of disease treatment (or cost
offsets). Interventions were considered “very cost-effective” if the
ACER was less than 1 times the per-capita gross domestic product
(GDP) (baht 110,000 in 2004) and “cost-effective” if between 1 and 3
times the per-capita GDP [31].
Second, we constructed an “expansion pathway” starting
ith themost cost-effective intervention. Next, we assessed the
ncremental cost-effectiveness ratios for the next best interven-
ion(s) to be added into an optimal intervention package. The
ncremental cost-effectiveness ratio was equal to the difference
n cost between the next intervention and the chosen interven-
ion package divided by the difference in health outcomes. We
ook into account shared costs and avoided double counting of
Fig. 1 – Cardiovascular disease prevention model. CVD,
cardiovascular disease; IHD, ischemic heart disease.ealth benefits.Probabilistic sensitivity analysis
Probabilistic sensitivity analysis (2000 iterations) was conducted
on the basis of distributions assigned to intervention costs and
effects, and disease treatment costs, using the Ersatz software
program (www.epigear.com). A lognormal distribution was as-
sumed for intervention effects, and a uniform distribution was
assumed for costs in the probabilistic uncertainty analysis.
Results
Three BP-lowering drug subclasses (D, CCB, and ACEI) were simi-
larly effective against IHD and stroke (Table 1). They were similar
to statins in their ability to reduce IHD risk butweremore effective
than statins in preventing stroke. The other two BP-lowering drug
subclasses (beta blocker and ARB) were somewhat less effective.
Intervention costs were dominated by the cost of health center
visits and laboratory tests.
Base-case analysis
A combination of three BP-lowering drugs (D  ACEI  CCB) was
dominant (i.e., intervention costs less than projected savings from
reduced treatment costs) in all risk categories (from 5%). The com-
bination of three BP-lowering drugs was more favorable than just
one or two of these drugs because the additional drugswere cheap
and resulted in more healthy life-years gained while saving more
disease treatment costs. Two other BP-lowering drugs with higher
ACERs were not considered in any of the drug combinations be-
cause it is unlikely that in primary prevention more than three
BP-lowering drugs would be prescribed.
As a single drug intervention compared with no treatment,
statins had a favorable cost-effectiveness ratio (Table 3). Adding
statins incrementally to the more cost-effective package of three
BP-lowering drugs, however, has a positive cost-effectiveness ra-
tio ranging fromahalf to one-and-a-half times the per-capita GDP,
depending on the absolute CVD risk category (Fig. 2 and Table 4).
Current practice was judged inefficient. Although the ACER fell
below the threshold of 3 times per-capita GDP, much more favor-
able treatment strategies are available.
Polypill
The polypill was a dominant intervention in all groups of more
than 5% 10-year CVD risk (Table 3). It produced slightly more ef-
fects than the use of the three BP-lowering drugs and statins to-
gether because of increased adherence, but it was much cheaper
because it reduced the need for laboratory tests and health center
visits (Fig. 2 and Table 3).
Probabilistic sensitivity analyses
The probabilistic sensitivity analyses revealed that the uncer-
tainty bounds (upper limits of 95% confidence intervals) for the
combinations of three BP-lowering drugs and the polypill did not
exceed the decision threshold of 1 time per-capita GDP in any risk
category of 5% or greater. Adding a statin to the three BP-lowering
drugs was associated with a 100%, 95%, and 57% probability of a
cost-effectiveness ratio below 3 times the per-capita GDP, for the
20%, 10% to 19%, and 5% to 9% CVD risk groups, respectively
(Table 4).
Discussion and Conclusion
Our results show that most of the drug combinations do not only
improve health but also save considerable future cost of disease
treatment. Primary CVD prevention with a polypill or a combina-
tion of three generic BP-lowering drugs in Thailand is very cost-
effective when the 10-year CVD risk is 5% or higher. We also ex-
Table 3 – Lifetime health gain, cost, and average cost-effectiveness ratios for single drugs and selected drug combinations by cardiovascular risk category.
Intervention Base-case analysis* Probabilistic analysis*
Health gain
(‘000s DALYs)
Net cost
(billion baht)
Cost-
effectiveness ratio*
(baht/DALY)
Median cost-
effectiveness ratio
(baht/DALY)
95%
uncertainty range
(baht/DALY)
Probability (%) of
falling below:
1  GDP 3  GDP
Current practice 400 120 300,000 N/A N/A N/A N/A
Cardiovascular disease risk in 10 years 5%9.9%
Polypill 1100 12 Dominant 16,000 (Dominant–41,000) 100 100
D  CCB  ACEI 890 1.4 Dominant 6,300 (Dominant–19,000) 100 100
D 420 5.8 14,000 21,000 (Dominant–56,000) 100 100
D  CCB  ACEI  statin 1000 18 17,000 50,000 (25,000–77,000) 100 100
CCB 380 13 33,000 45,000 (21,000–75,000) 100 100
ACEI 280 9.3 33,000 89,000 (53,000–140,000) 82 100
BB 190 14 70,000 200,000 (88,000–1,300,000) 6 70
Statin 260 24 90,000 180,000 (85,000–290,000) 11 99
ARB 250 31 120,000 310,000 (180,000–620,000) 0 58
Cardiovascular disease risk in 10 years 10%19.9%
Polypill 910 16 Dominant 2,600 (Dominant–22,000) 100 100
D  CCB  ACEI 720 7.3 Dominant Dominant (Dominant–7,000) 100 100
D 330 0.9 3,000 8,700 (Dominant–40,000) 100 100
D  CCB  ACEI  statin 840 2.9 3,000 28,000 (8,800–49,000) 100 100
CCB 310 5.0 16,000 27,000 (5,800–24,000) 100 100
ACEI 220 3.2 15,000 58,000 (28,000–130,000) 99 100
BB 150 6.7 44,000 180,000 (57,000–1,000,000) 18 82
Statin 210 12 56,000 120,000 (48,000–210,000) 41 100
ARB 200 17 83,000 230,000 (120,000–470,000) 1 86
Cardiovascular disease risk in 10 years 20%
Polypill 720 16 Dominant Dominant (Dominant–4,900) 100 100
D  CCB  ACEI 570 9.4 Dominant Dominant (Dominant–Dominant) 100 100
D 270 1.8 Dominant Dominant (Dominant–21,000) 100 100
D  CCB  ACEI  statin 660 5.2 Dominant 8,100 (Dominant–22,000) 100 100
CCB 350 0.4 1,000 9,400 (Dominant–30,000) 100 100
ACEI 180 0.1 Dominant 29,000 (7,000–62,000) 100 100
BB 120 2.3 18,000 110,000 (27,000–580,000) 53 93
Statin 160 4 24,000 69,000 (20,000–130,000) 91 100
ARB 160 6.9 43,000 140,000 (70,000–280,000) 28 99
Note. Numbers are rounded to two significant digits.
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta blocker; CCB, calcium channel blocker; D, diuretic; DALY, disability-adjusted life-years; GDP, gross
domestic product; N/A, not applicable.
* Drug costs used in base-case analysis are the lowest annual costs (for generic versions of the drugs), whereas ranges used in the probabilistic uncertainty analysis are between the lowest and the
highest costs shown on the Ministry of Public Health Web page.
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BP-lowering drugs. Against a threshold of 3 times the per-capita
GDP, this is cost-effective for the 10-year absolute risk category of
20% but perhaps not for the lower risk categories. The potential
or health gain is very large if the coverage of three generic BP-
owering drugs is extended to everyone at even modestly in-
reased CVD risk (10-year CVD risk of 5% and greater). This could
ead to an estimated increase in life expectancy of 0.48 year in the
ohort of Thai people aged 30 years and above with this risk level
4,000,000 life-years gained in a population of 8,274,248).
A major strength of our study is that costs and disease param-
eters were based on local data. The effectiveness of CVD preven-
tion drugs is well established in the international literature. Al-
though most of the data on effectiveness come from Western
countries, a study on associations of BP and cholesterol (as risk
factors) and CVD shows that RRs of IHD and stroke associatedwith
an increase in these two risk factors in Thailand are comparable to
those in the Asia-Pacific and Western populations [32]. Our anal-
ysis is limited by several assumptions. We assumed the same ef-
fects for the drugs of the same class because there was no study of
primary prevention that directly compared individual drugs
within the same class and measured health outcomes. Two Co-
chrane reviews of trials that evaluated the dose-related BP-lower-
ing efficacy of different ACEIs and of different ARBs against pla-
cebo, however, showed no clinically meaningful BP-lowering
differences betweendifferent ACEIs or ARBs [33,34].We assumed a
50% adherence rate for interventions, which is lower than that
reported in trials but similar to findings in routine care elsewhere
[35]. The adherence rate is not a critical assumption in calculating
cost-effectiveness ratios because both costs and effectiveness of
interventions increase or decrease in the same direction. We as-
sumed higher adherence for the polypill because one pill is more
convenient to take and it would have fewer side effects due to
reduced doses of BP-lowering drugs and the general safety profile
of statins [11]. We did not model the cost and consequences of
dverse drug reactions. Although the literature reports the propor-
ion of people with adverse drug reactions, data on the cost asso-
iated with the treatment of these were not available in Thailand.
ost side effects of these drugs, however, are minor [23,30].
A similar study in Argentina shows different results [19]. Pop-
ulation-wide approaches (health education through mass media
and reduction of salt in bread through voluntary agreement with
industry) and a polypill used in amoderate risk groupwith 10-year
Fig. 2 – Intervention pathway of lifetime DALYs averted
and total costs associated with the ideal mix of blood
pressure- and cholesterol-lowering drugs for
cardiovascular disease prevention in Thailand. BP, blood
pressure; DALY, disability-adjusted life-years.CVD risk of 10% and higher were the cost-effective interventions.T P 1 2 3 4 5 6 N A *
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21V A L U E I N H E A L T H R E G I O N A L I S S U E S 1 ( 2 0 1 2 ) 1 5 – 2 2Treatmentwith BP-lowering drugs and statins, and the polypill for
population subgroups with absolute CVD risks below 10%, were
not cost-effective against a threshold of 1 time the per-capita GDP.
This is due to the much higher costs of drugs in Argentina [19].
Similarly, the primary prevention of CVD by using statins in the
UK population with coronary heart disease risks of below 3% per
year (30% risk over 10 years) was not cost-effective, [18] again
ue to high drug prices.
The design used in this study [31] provides information on the
potential to reallocate health care resources formore efficient pre-
vention of CVD in the country. Currently, CVD preventive drug
treatment has very low coverage, is not targeted to those at in-
creased absolute risk, and is inefficient because expensive drugs
are prescribed in preference to cheap generics. Given the potential
health gain and cost savings of disease treatment in the future, we
recommend that Thailand’s first priority be to reallocate health
care resources toward greater utilization of generic drug combina-
tions.
Once a polypill is locally produced, a follow-up study should be
conducted to evaluate whether the drug produces the expected
reduction in CVD incidence and adherence. The barriers to the
utilization of generic drugs for CVD prevention should also be fur-
ther investigated. Although generic drugs are very cost-effective
for CVD prevention, putting a large proportion of the population
on lifelong medication (15 million Thais have 10-year CVD risks
of5%)may not be considered desirable. Further research for CVD
prevention in Thailand should focus on the cost-effectiveness of
interventions that reduce exposure to risk factors for CVD such as
smoking cessation [36], salt reduction strategies [10], and diabetes
mellitus prevention [37].
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